SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the ...
At the European Society of Cardiology (ESC) Congress 2025, findings from a post-hoc analysis of the SURMOUNT-5 trial (NCT05822830) were presented, comparing tirzepatide to semaglutide for their impact ...
Oral micronutrient supplementation showed no benefit on geographic atrophy lesion growth among a patient group from the OAKS and DERBY trials, according to a speaker ...
This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” Clinical trials of newly developed drugs often don’t ...
In a post-hoc analysis of the ADVANCE and MOTIVATE phase III induction studies, along with the FORTIFY maintenance study, researchers evaluated the safety profile of risankizumab (Skyrizi) in patients ...
A lower-than-recommended dose of edoxaban (Savaysa; Daiichi Sankyo) lessens bleeding without compromising protection against ischemic events in elderly patients with atrial fibrillation (AF), a post ...
Systematic assessment of tumor mutational burden calculation across different sequencing platforms and cancer types and its implication in clinical decision-making.
MedPage Today on MSN
Higher-Dose Aflibercept Similar to Standard Dose in Severe AMD Variant
In a subgroup analysis of patients with polypoidal choroidal vasculopathy, aflibercept 8 mg achieved similar vision gains to the standard 2-mg dose while allowing a longer treatment interval. An ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback